We support:


Most drugs are small molecules with molecular weights typically less than 1500 daltons. We have developed LC-MS assays for over 40 commercially available drugs and over 3500 new chemical entities. The assay can be optimized for the biological (plasma, csf, urine) and non-biological matrix (in vitro solutions, environmental samples) of interest.


Drug development of novel therapeutics can include larger protein molecules. We have the capability to use LC-MS assays to quantify therapeutic peptides and proteins. Please contact us for further details to ensure that we can adequately support your assay needs.


Understanding the concentration of your compound in target tissues is essential. We have a state of the art bead-beater system to homogenize animal, plant, and microbiologic samples to quantify extracellular and intercellular concentrations of your compound or metabolites of interest.


The effect or safety of your compound may be measurable in vivo through measurement of biomarkers. LC-MS assays can measure amino acids and bile acids to support metabolomics and assessment of physiologic changes This may be particularly helpful for longitudinal assessment of compounds in vivo.


The activity of your compound may be influenced by numerous physiochemical variables that impact the stability and integrity of your agent. We can help you understand the in vitro stability of your compound based on environmental factors or acceptable excursion standards. Pharmaceutical modifications may help to improve the solubility and stability of your compound in vivo.

We have state-of-the art mass spectrometry instruments and technical expertise to meet your low sensitivity and high specificity needs. Our analytical methods are run in accordance with FDA guidance for calibration curve, specificity, precision and accuracy, extraction recovery, matrix effect, and dilution integrity standards. We can help you overcome assay development obstacles that you may be facing.


Listing Row

Tuesday, September 10, 2013
Tuesday, September 10, 2013